Abvc Biopharma, Inc. (ABVC) Stock Price & Analysis
Abvc Biopharma, Inc. (ABVC) fell 4.17% to USD 1.15 as of July 25, 2026 at 10:03 UTC, according to Nexqual real-time market data.
ABVC last closed at USD 1.2; the session ranged USD 1.15–1.2 on volume of 84,341 shares. Market capitalization is $29.90M, with a 52-week range of USD 0.88–3.4 (NCM). Source: Nexqual, July 25, 2026 at 10:03 UTC.
Key Statistics (as of July 25, 2026 at 10:03 UTC)
| Price | USD 1.15 |
|---|---|
| Change | ▼ 4.17% (down) |
| Previous Close | USD 1.2 |
| Open | USD 1.2 |
| Day Range | USD 1.15 – 1.2 |
| 52-Week Range | USD 0.88 – 3.4 |
| Volume | 84,341 shares |
| Market Cap | $29.90M |
| Exchange | NCM |
Technical Analysis (ABVC)
Nexqual's technical model rates ABVC "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 10:03 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.58 (neutral) |
| vs SMA50 | Below (USD 1.35) |
| MACD | -0.07 (negative) |
Analyst Ratings (ABVC)
Wall Street analysts rate ABVC "None", per Nexqual as of July 25, 2026 at 10:03 UTC.
| Consensus Rating | None |
|---|
Earnings (ABVC)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-03-31 | USD -0.6 vs est -0.5 ▼ miss |
| 2022-12-31 | USD -1.5 vs est -1.5 ▲ beat |
| 2022-09-30 | USD -1.1 vs est -2 ▲ beat |
| 2022-06-30 | USD -0.6 vs est -1.25 ▲ beat |
Source: Nexqual, July 25, 2026 at 10:03 UTC.
Financials & Fundamentals (ABVC)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -87.78% |
| Debt / Equity | 21.29 |
| Current Ratio | 0.12 |
| Total Cash | $202,509 |
| Total Debt | $2.73M |
| Free Cash Flow | $1.16M |
Source: Nexqual, July 25, 2026 at 10:03 UTC.
Financial Health Score (ABVC)
Nexqual rates Abvc Biopharma, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 10:03 UTC.
| Growth | Strong — Revenue +173% YoY (annual) |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Solid — $203K cash vs $3M debt |
| Cash Flow | Strong — FCF $1M, 119% margin |
| Efficiency | Critical — ROE -88%, ROA -29.0% |
Ownership (ABVC)
| Insider Ownership | +18.57% |
|---|---|
| Institutional Ownership | +3.14% |
| Shares Outstanding | 26.00M |
| Float | 20.44M |
| Short % of Float | +2.20% |
Source: Nexqual, July 25, 2026 at 10:03 UTC.
Leadership (ABVC)
Abvc Biopharma, Inc. is led by Uttam Yashwant Patil (age 39), CEO & Interim CFO, per Nexqual as of July 25, 2026 at 10:03 UTC.
| CEO & Interim CFO | Uttam Yashwant Patil (age 39) |
|---|---|
| Chairman & Chief Business Officer | Eugene Jiang (age 39) |
| Chief Scientific Officer, Chief Strategy Officer & Director | Tsung-Shann Jiang EMBA (age 71) |
Major Backers & Investors (ABVC)
Notable institutional backers of Abvc Biopharma, Inc. include Fidelity, Renaissance Technologies, according to Nexqual as of July 25, 2026 at 10:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.67% |
| Renaissance Technologies | 0.37% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.83% |
| Geode Capital | 0.85% |
| State Street | 0.28% |
| BlackRock | 0.22% |
| Northern Trust | 0.12% |
Source: Nexqual, July 25, 2026 at 10:03 UTC.
From Abvc Biopharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States.
- The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.
- It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer.
- The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BBLG | Bone Biologics Corp | USD 1.07 | ▼ 2.73% |
| RNAZ | TransCode Therapeutics, Inc. | USD 5.93 | ▼ 29.4% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.26 | ▼ 7.96% |
| BTTX | Better Therapeutics, Inc. | USD 0 | ▲ 0% |
| EVAX | Evaxion A/S | USD 2.96 | ▼ 2.63% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 10:03 UTC. This page is informational and not investment advice.